Defining the new field of longevity medicine

A consortium of scientists and medical doctors have collaborated to define the new field of longevity medicine.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

A consortium of scientists and medical doctors have collaborated to define the new field of longevity medicine.

Today, a group of scientists and medical doctors including scientists from Deep Longevity, a company mainly engaged in the development of explainable artificial intelligence systems to track aging rates on multiple levels, announced a research collaboration and the launch of the Longevity Medicine 201, an extended longevity medicine course for physicians. It is the second course in the Longevity Medicine course series, the first one being the 2.5h-hour Longevity Medicine 101 (an introduction to longevity medicine for physicians course), which is already available on multiple platforms and received CME accreditation in August 2021.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE